## Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

Adamas Pha Form 4	rmaceuticals Inc										
Form 4 February 27	2015										
								OMB APPROVAL			
Check th if no lon subject t	iis box ger STATEN	Washington, D.C. 20549								3235-0287 January 31, 2005 average	
Section Form 4 of Form 5 obligation may con <i>See</i> Instr 1(b).	16. or Filed pur ons tinue. Section 17(	SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940							burden hou response	urs per	
(Print or Type	Responses)										
1. Name and Address of Reporting Person <u>*</u> Went Gregory T			2. Issuer Name <b>and</b> Ticker or Trading Symbol Adamas Pharmaceuticals Inc [ADMS]				ng	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
	. , ,	Middle) C., 1900	3. Date of	of Earliest Tr Day/Year)	ransaction			X Director X Officer (giv below) Chief	X 10 ve titleOth below) Executive Offi	ner (specify	
File				. If Amendment, Date Original ïled(Month/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
EMERYVI	LLE, CA 94608							Person		oporting	
(City)	(State)	(Zip)	Tab	ole I - Non-I	Derivative	Secu	rities A	cquired, Disposed o	of, or Beneficia	lly Owned	
1.Title of Security2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date any (Month/Day/Year)(Instr. 3)any (Month/Day/Year)		Date, if	Code Disposed of (D)			Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect			
D . I . D			c	Code V			Price				
Reminder: Rep	port on a separate line	e for each cla	ass of sec	urities benef	icially ow	ned di	rectly o	or indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date 3A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)		4. 5. Number of TransactiorDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)8((	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 17.31	02/25/2015		А	75,000	<u>(1)</u>	02/24/2025	Common Stock	75,000

## Edgar Filing: Adamas Pharmaceuticals Inc - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Went Gregory T C/O ADAMAS PHARMACEUTICALS, INC. 1900 POWELL ST., SUITE 750 EMERYVILLE, CA 94608	Х	Х	Chief Executive Officer			
Signatures						

/s/Grace Shin, as 02/27/2015 Attorney-in-Fact

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The Option shares shall vest as follows: 1/48th of the option shares shall vest on the 1st of each month beginning with March 1, 2015, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.